Memo Therapeutics increases Series C financing to CHF 45 million

by Ysios Capital

Memo Therapeutics AG, a late-stage biotech company developing a best-in-class BKV-neutralizing antibody for BKV infection in kidney transplantation, today announces that it has successfully raised CHF...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

HappyMami strengthens its growth with th...

by Eoniq.fund

Founded by professionals with expertise in breastfeeding, engineering ...

Photos Stream